Trial Profile
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Sep 2017
Price :
$35
*
At a glance
- Drugs Vilazodone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Pharmacogenomic; Registrational
- Sponsors PGxHealth
- 23 Nov 2010 Results presented at the U.S. Psychiatric & Mental Health Congress.
- 26 May 2010 Positive results data from this trial will be presented at the annual meeting of the American Psychiatric Association (APA 2010), according to a Clinical Data Inc media release.
- 09 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.